

8. Concerns of the nuclear medicine community regarding reliable supply of ^{99m}Tc post-2016


Estimate of Japan's Post-2016 Demand for ^{99m}Tc

Takashi YAMASHITA, M.D., Ph.D. Executive Director Japan Radioisotope Association

July 9, 2013 HLG-MR Meeting in Paris




Japan's Sources of Diagnostic and Therapeutic Radiopharmaceuticals





Global Supply and Examinations in 2008 Total demand is 12,000 Ci/6dCi/w



	N-America	Europe	📕 Japan		Others	Total
Exams	15,000,000	12,000,000	910,000	2,	100,000	30,000,000
Demand	23.7	10.8	5.3		7.6	47.4 Million doses




Nationwide Survey of Radiopharmaceutical Examinations in Japan






Shift to PET (FY2001-2012)





Current and Future Tc-99m Examinations in Japan






Plan for Future Domestic ⁹⁹Mo/^{99m}Tc Production

⁹⁸Mo(n,γ)⁹⁹Mo

JAEA plans to produce 99 Mo by (n, γ) reaction with its JMTR(Japan Materials Testing Reactor, 50MW).JMTR will supply up to 25% of Japanese demand.

Radiopharmaceutical factories will supply ^{99m}Tcradiopharmaceuticals using ⁹⁹Mo.



¹⁰⁰Mo(p,pn)⁹⁹Mo &¹⁰⁰Mo(p,2n)^{99m}Tc

NIRS (National Institute of Radiological Sciences) has succeeded in producing ⁹⁹Mo/^{99m}Tc using an ultra-small cyclotron.





Outstanding Issues of Domestic Production

- 1. Low specific activity of ⁹⁹Mo
- 2. Method to separate ^{99m}Tc from ⁹⁹Mo
- 3. No precise estimate of production cost
- 4. Reactor shutdown in wake of Fukushima accident



Conclusions:

- 1. Accelerated decrease of ⁹⁹Mo/^{99m}Tc examinations after 2016.
- PET or MRI to replace about half ⁹⁹Mo/^{99m}Tc examinations in 2027.
- Fukushima disaster affecting domestic production of ⁹⁹Mo/^{99m}Tc.
- Closely coordinated international response under auspices of HLG-MR required for a constant supply of ⁹⁹Mo/^{99m}Tc and other radioisotopes.

http://www.jrias.or.jp/index.html